Hematology News

Evidence suggests two investigational gene therapies provide net health benefits compared with standard approaches for sickle cell disease, according to a revised evidence report from Institute for Clinical and Economic Review.

Direct oral anticoagulants for cancer-associated thrombosis appeared associated with lower risk for venous thromboembolism recurrence and major bleeds, as well as a reduction in mortality rates, among patients with cancer.

Researchers have identified a direct correlation between blood group A and increased risk for COVID-19 infection, according to study results published in Blood.

An experimental gene editing cell therapy for sickle cell disease has shown encouraging early results in a phase 1/phase 2 multicenter clinical trial, according to researchers at Cleveland Clinic Children’s.

Genomic alteration using adenine base editors demonstrated the most potency in restarting fetal hemoglobin expression in cells of patients with sickle cell disease, study results showed.

Thrombophilia is a known risk factor for venous thromboembolism, but the value of thrombophilia testing in guiding treatment decisions remains a topic of debate.

Crizanlizumab did not reduce organ support-free days or in-hospital mortality among patients hospitalized with moderate to severe COVID-19, according to study results presented at International Society on Thrombosis and Hemostasis Congress.

Patient-relevant bleeding negatively affected quality of life and treatment adherence among patients on anticoagulant therapy, according to results of a survey presented at International Society on Thrombosis and Hemostasis Congress.

The FDA announced several regulatory actions the past few weeks.

FDA approved valoctocogene roxaparvovec-rvox for the treatment of certain adults with severe hemophilia A, according to the agent’s manufacturer.